Literature DB >> 12201173

Characterisation & drug susceptibility patterns of extrapulmonary mycobacterial isolates.

Ranjana Sachdeva1, D V Gadre, Vibha Talwar.   

Abstract

BACKGROUND &
OBJECTIVES: There is a paucity of information on extrapulmonary tuberculosis as much of the attention is focussed on pulmonary tuberculosis. This prospective study aimed at identification and characterisation of mycobacterial isolates from extra pulmonary sites and the evaluation of the drug susceptibility patterns of Mycobacterium tuberculosis isolates from extrapulmonary sites using the conventional method and the E-test.
METHODS: A total of 350 specimens from patients of extrapulmonary tuberculosis with varied presentation, were studied. Speciation and characterisation of isolates were done on the basis of growth and biochemical characteristics. Drug susceptibility testing for M. tuberculosis isolates was done by proportion method for isoniazid, rifampicin, ethambutol and pyrazinamide, whereas resistance ratio method was used for streptomycin. E-test (AB Biodisk, Sweden) was carried out to compare susceptibility patterns of the M. tuberculosis isolates for isoniazid and rifampicin with the conventional method.
RESULTS: Thirty two of 350 (9.14%) patients clinically suspected to have extrapulmonary tuberculosis were culture positive for mycobacteria. On characterisation, 20 of the 32 isolates were identified as M. tuberculosis and 12 as non-tubercular mycobacteria (NTM) with 5 of the 12 being Mycobacterium avium complex. Among M. tuberculosis isolates both initial and acquired resistance was highest for streptomycin followed by isoniazid, rifampicin and ethambutol. No strain showed resistance to pyrazinamide. Two strains were found to be multidrug resistant. Drug susceptibility patterns by conventional method corroborate with the E-test results. INTERPRETATION &
CONCLUSION: This study shows that the characterisation and species identification of mycobacterial isolates along with drug susceptibility testing help in better understanding of extrapulmonary tuberculosis. E-test had the advantage of being rapid and simple without need for additional equipment.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12201173

Source DB:  PubMed          Journal:  Indian J Med Res        ISSN: 0971-5916            Impact factor:   2.375


  6 in total

1.  Acid-fast bacilli culture positivity and drug resistance in abdominal tuberculosis in Mumbai, India.

Authors:  Hrishikesh Samant; Devendra Desai; Philip Abraham; Anand Joshi; Tarun Gupta; Camilla Rodrigues; Siji George
Journal:  Indian J Gastroenterol       Date:  2014-06-15

2.  Comparative study for determination of Mycobacterium tuberculosis susceptibility to first- and second-line antituberculosis drugs by the Etest using 7H11, blood, and chocolate agar.

Authors:  Ahmet Yilmaz Coban; Kemal Bilgin; Meltem Uzun; Alper Akgunes; Anne Yusof; Belma Durupinar
Journal:  J Clin Microbiol       Date:  2008-10-22       Impact factor: 5.948

3.  Non tuberculous mycobacteria in surgical wounds- a rising cause of concern?

Authors:  Amit Kumar Shah; R P S Gambhir; Nandita Hazra; R Katoch
Journal:  Indian J Surg       Date:  2010-08-26       Impact factor: 0.656

4.  Molecular analysis of Mycobacterium isolates from extrapulmonary specimens obtained from patients in Mexico.

Authors:  Cosme Alvarado-Esquivel; Nora García-Corral; David Carrero-Dominguez; José Antonio Enciso-Moreno; Teodoro Gurrola-Morales; Leopoldo Portillo-Gómez; Rudi Rossau; Wouter Mijs
Journal:  BMC Clin Pathol       Date:  2009-03-09

5.  Drug resistance among extrapulmonary TB patients: Six years experience from a supranational reference laboratory.

Authors:  Azger Dusthackeer; Gomathi Sekar; Shambhavi Chidambaram; Vanaja Kumar; Pranav Mehta; Soumya Swaminathan
Journal:  Indian J Med Res       Date:  2015-11       Impact factor: 2.375

6.  Rapid Screening of MDR-TB in Cases of Extra Pulmonary Tuberculosis Using Geno Type MTBDRplus.

Authors:  Richa Kumari; Rajneesh Tripathi; Alok Prakash Pandey; Tuhina Banerjee; Pallavi Sinha; Shampa Anupurba
Journal:  PLoS One       Date:  2016-07-21       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.